Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cardiovascular Disorders
Published in: BMC Cardiovascular Disorders 1/2016

Open Access 01-12-2016 | Review

Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention

Authors: Erhan Tenekecioglu, Vasim Farooq, Christos V. Bourantas, Rafael Cavalcante Silva, Yoshinobu Onuma, Mustafa Yılmaz, Patrick W. Serruys

Published in: BMC Cardiovascular Disorders | Issue 1/2016

Login to get access

Abstract

Numerous advances and innovative therapies have been introduced in interventional cardiology over the recent years, since the first introduction of balloon angioplasty, but bioresorbable scaffold is certainly one of the most exciting and attracting one. Despite the fact that the metallic drug-eluting stents have significantly diminished the re-stenosis ratio, they have considerable limitations including the hypersensitivity reaction to the polymer that can cause local inflammation, the risk of neo-atherosclerotic lesion formation which can lead to late stent failure as well as the fact that they may preclude surgical revascularization and distort vessel physiology. Bioresorbable scaffolds overcome these limitations as they have the ability to dissolve after providing temporary scaffolding which safeguards vessel patency. In this article we review the recent developments in the field and provide an overview of the devices and the evidence that support their efficacy in the treatment of CAD. Currently 3 devices are CE marked and in clinical use. Additional 24 companies are developing these kind of coronary devices. Most frequently used material is PLLA followed by magnesium.
Literature
1.
2.
Farooq V, Gogas BD, Serruys PW. Restenosis: delineating the numerous causes of drug-eluting stent restenosis. Circ Cardiovasc Interv. 2011;4(2):195–205.CrossRefPubMed
3.
Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301:61–8.CrossRefPubMed
4.
Sigwart U, Urban P, Golf S, Kaufmann U, Imbert C, Fischer A, et al. Emergency stenting for acute occlusion after coronary balloon angioplasty. Circulation. 1988;78:1121–7.CrossRefPubMed
5.
Roubin GS, Cannon AD, Agrawal SK, Macander PJ, Dean LS, Baxley WA, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation. 1992;85:916–27.CrossRefPubMed
6.
Serruys PW, Strauss BH, Beatt KJ, Bertrand ME, Puel J, Rickards AF, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med. 1991;324:13–7.CrossRefPubMed
7.
Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331:489–95.CrossRefPubMed
8.
Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331:496–501.CrossRefPubMed
9.
Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996;94:1247–54.CrossRefPubMed
10.
Gordon PC, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE, Baim DS. Mechanisms of restenosis and redilation within coronary stents—quantitative angiographic assessment. J Am Coll Cardiol. 1993;21:1166–74.CrossRefPubMed
11.
Karas SP, Gravanis MB, Santoian EC, Robinson KA, Anderberg KA, King SB. Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol. 1992;20:467–74.CrossRefPubMed
12.
Dussaillant GR, Mintz GS, Pichard AD, Kent KM, Satler LF, Popma JJ, et al. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. J Am Coll Cardiol. 1995;26:720–4.CrossRefPubMed
13.
Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and intravascularultrasound follow-up. Circulation. 2001;104:2007–11.CrossRefPubMed
14.
Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–31.CrossRefPubMed
15.
Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet. 2007;369:667–78.CrossRefPubMed
16.
Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice: 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008;52:1134–40.CrossRefPubMed
17.
Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109(6):701–5.CrossRefPubMed
18.
Serruys PW, Onuma Y, Garg S, Vranckx P, De Bruyne B, Morice MC, et al. ARTS II Investigators. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol. 2010;55:1093–101.CrossRefPubMed
19.
Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J. 2006;27:166–70.CrossRefPubMed
20.
Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol. 2005;46:231–6.CrossRefPubMed
21.
Shalaby SW, Burg KJL. Absorbable and Biodegradable Polymers (Advances in Polymeric Biomaterials). Boca Raton, FL: CRC Press; 2003.CrossRef
22.
Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371:899–907.CrossRefPubMed
23.
Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich A. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart. 2003;89:651–6.CrossRefPubMedPubMedCentral
24.
Waksman R, Pakala R, Kuchulakanti PK, Baffour R, Hellinga D, Seabron R, et al. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv. 2006;68:607–17.CrossRefPubMed
25.
26.
Brugaletta S, Radu MD, Garcia-Garcia HM, Heo JH, Farooq V, Girasis C, et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis. 2012;221:106–12.CrossRefPubMed
27.
Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193–202.CrossRefPubMed
28.
Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, García-García HM, et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation. 2010;122:2288–300.CrossRefPubMed
29.
Garg S, Serruys P, Onuma Y, Dorange C, Veldhof S, Miquel-Hébert K, et al. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2009;2(12):1190–8.CrossRefPubMed
30.
Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, et al. A next-generation bioresorbable coronary scaffold system-from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. J Am Coll Cardiol Intv. 2014;7:89–99.CrossRef
31.
Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B, et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy. Eur Heart J. 2012;33:1325–33.CrossRefPubMed
32.
Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: A prospective, non-randomised multicentre trial. Lancet. 2007;369:1869–75.CrossRefPubMed
33.
Barlis P, Tanigawa J, Di Mario C. Coronary bioabsorbable magnesium stent: 15-month intravascular ultrasound and optical coherence tomography findings. Eur Heart J. 2007;28:2319.CrossRefPubMed
34.
Ghimire G, Spiro J, Kharbanda R, Roughton M, Barlis P, Mason M, et al. Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. EuroIntervention. 2009;4:481–4.CrossRefPubMed
35.
Haude M, Erbel R, Erne P, Verheye S, Degen H, Böse D, et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet. 2013;381(9869):836–44.CrossRefPubMed
36.
Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102:399–404.CrossRefPubMed
37.
Tsuji T, Tamai H, Igaki K, Hsu Y-S, Kosuga K, Hata T, et al. Four-year follow-up of the biodegradable stent (Igaki-Tamai stent). Circ J. 2004;68:135.CrossRef
38.
Nishio S. Long-term (>10 years) clinical outcomes of first-in-man biodegradable poly-l-lactic acid coronary stents. Eurointervenion. 2010;6:H44.CrossRef
39.
Biamino G, Schmidt A, Scheinert D. Treatment of SFA lesions with PLLA biodegradable stents: results of the PERSEUS Study. J Endovasc Ther. 2005;12:5.
40.
Schulze R. REVA Medical, Inc. Bioresorbable stent. In: Cardiovascular Revascularization Therapies 2007.
41.
Grube E. Bioabsorbable stent: the Boston Scientific and REVA technology. Presented at: EuroPCR; May 19–22, 2009; Barcelona, Spain.
42.
Costa RA. REVA ReZolve clinical program update. In: Transcatheter Cardiovascular Therapeutics, Miami Beach, FL, 2012.
43.
44.
Abizaid A. Cardiovascular Research Technologies (CRT) 2015.
45.
Jabara R, Chronos N, Robinson K. Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating. Catheter Cardiovasc Interv. 2008;72:186–94.CrossRefPubMed
46.
Jabara R, Pendyala L, Geva S, Chen J, Chronos N, Robinson K. Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. EuroIntervention. 2009;5:F58–64.CrossRefPubMed
47.
Verheye S. First-in-man results with a myolimus-eluting bioresorbable PLLA-based vascular scaffold.Presented in Transcatheter Cardiovasc Therapeutics. Miami Beach , FL; October 23rd 2012.USA.
48.
48:Verheye S. DESolve Nx Novolimus-Eluting PLLA-Based BRS: First Report of the 6-month OCT and 12-month Clinical and Imaging Result. Presented in Transcatheter Cardiovasc Therapeutics. San Fransisco, CA, USA; October 27th 2013.
49.
Abizaid A. Prospective, Multicenter Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and 2-Year Clinical Results. Presented in Transcatheter Cardiovasc Therapeutics. Washington, DC. USA; September 16th 2014.
50.
Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897–910.CrossRefPubMed
51.
Onuma Y, Serruys P, Ormiston J, Regar E, Webster M, Thuesen L, et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: The ABSORB trial. EuroIntervention. 2010;6:447–53.CrossRefPubMed
52.
Tanimoto S, Serruys PW, Thuesen L, Dudek D, de Bruyne B, Chevalier B, et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus- eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT Trials. Cathet Cardiovasc Interv. 2007;70:515–23.CrossRef
53.
Garg S, Serruys P. Biodegradable stents and nonbiodegradable stents. Minerva Cardioangiol. 2009;57:537–65.PubMed
54.
Ormiston JA, Serruys PW, Onuma Y, van Geuns RJ, de Bruyne B, Dudek D, et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv. 2012;5:620–32.CrossRefPubMed
55.
Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011;58:1578–88.CrossRefPubMed
56.
Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de Bruyne B, et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention. 2014;9(11):1271–84.CrossRefPubMed
57.
Serruys PW, Chevalier B, Dudek D, Cequier A, Carrie D, Iniguez A, et al. A bioresorbable everolimus-eluting scaff old versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385:43–54.CrossRefPubMed
58.
Dudek D, Rzeszutko Ł, Zasada W, Depukat R, Siudak Z, Ochała A. Bioresorbable vascular scaffolds in patients with acute coronary syndromes : the POLAR ACS study. Pol Arch Med Wewn. 2014;124(12):669–77.PubMed
59.
Lafont A, Durand E. A.R.T. concept of a bioresorbable stent without drug elution. EuroIntervention. 2009;5(Suppl F):F83–7.CrossRefPubMed
60.
Durand E, Lemitre M, Couty L, Sharkawi T, Brasselet C, Vert M, et al. Adjusting a polymer formulation for an optimal bioresorbable stent: a 6-month follow-up study. EuroIntervention. 2012;8:242–9.CrossRefPubMed
61.
Fajadet J. The ART, stent: design and early first-in-man experiences.Presented in Transcatheter Cardiovasc Therapeutics. Miami Beach , FL, USA; October 23rd 2012.
62.
Lafont A. ARTDIVA. Presented in BRS 2014. Boston, MA, USA; July 6th 2014.
63.
Shen L, Wang Q, Wu Y, Xie J, Zhang F, Ge L, et al. Preliminary evaluation of fully bioabsorbable PLLA sirolimus eluting stents in a porcine model. Chin J Intervent Cardiol. 2009;19:301–5.
64.
Shen L, Wang Q, Wu Y, Xie J, Ge J. Short-term effects of sirolimus eluting fully bioabsorbable polymeric coronary stents in a porcine model. Transcatheter Cardiovasc Ther 2011
65.
65:Wu Y, Shen L, Yao Z, Ge L, Wang Q, Qian J, et al. Long-term Angiographic and Optical Coherence Tomography Follow-up of XINSORB Scaffold in Porcine Coronary Model.Abstract presentation in Transcatheter Cardiovasc Therapeutics 2014. Washington, DC. USA; September 13-17 2014.
66.
Ge J. BRS Under Development III – The XINSORB BRS. Presented in Transcatheter Cardiovasc Therapeutics. Washington, DC. USA; September 16th 2014.
67.
Santoso T. The Mirage Bioresorbable Microfiber Scaffold (BRMS) Manli Cardiology. Presented in Transcatheter Cardiovasc Therapeutics. Washington, DC. USA; September 16th 2014.
68.
Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention. 2015;10(9):1024–94.CrossRefPubMed
69.
Mitsutake Y, Ueno T, Ikeno F, Yokoyama S, Sasaki K, Ohtsuka M, et al. Second-generation everolimus-eluting stents demonstrate better vascular function, less thrombus formation, and less yellow intima than first-generation drug-eluting stents. AsiaIntervention. 2015;1:33–40.
70.
Metadata
Title
Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention
Authors
Erhan Tenekecioglu
Vasim Farooq
Christos V. Bourantas
Rafael Cavalcante Silva
Yoshinobu Onuma
Mustafa Yılmaz
Patrick W. Serruys
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2016
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-016-0207-5

Other articles of this Issue 1/2016

BMC Cardiovascular Disorders 1/2016 Go to the issue

Research article

Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies

Research article

Left atrial appendage morphology, echocardiographic characterization, procedural data and in-hospital outcome of patients receiving left atrial appendage occlusion device implantation: a prospective observational study

Research article

Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis

Research article

Cardioprotection provided by Echinatin against ischemia/reperfusion in isolated rat hearts

Research article

Relationship between hsTnI and coronary stenosis in asymptomatic women with rheumatoid arthritis

Research article

Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits